You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

455 Results
Guidelines and Advice
Status: Archived
ID: DICRC
Sep 2012
Guidelines and Advice
Status: Current
ID: GL-C50-28
Dec 2016
Guidelines and Advice
Status: Current
ID: ES PET 16
Version: 2
Apr 2024
Guidelines and Advice
Status: Current
ID: PET 11
Aug 2011
Guidelines and Advice
Status: Current
ID: GL-C50-31
Mar 2017
Statistical Reports
Cancer facts
Mar 2023
Statistical Reports
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Exceptional Access Program
    lapatinib - Second-Line treatment of HER2 positive metastatic breast cancer in combination with chemotherapy after previous exposure to trastuzumab based treatments, with specific criteria
Exceptional Access Program
    lapatinib - Treatment of HER-2 positive metastatic breast cancer when used in combination with chemotherapy after use of trastuzumab in patients who have an adverse drug reaction or contraindication to trastuzumab therapy
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
capecitabine,
lapatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Jul 2025

Pages